# Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

> **NCT00276692** · PHASE2 · COMPLETED · sponsor: **Children's Cancer and Leukaemia Group** · enrollment: 35 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00276692
- **Lead sponsor:** Children's Cancer and Leukaemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2008-09
- **Final completion:** 2009-07
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276692, "Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00276692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*